|Day Low/High||34.03 / 34.62|
|52 Wk Low/High||17.06 / 44.50|
Today's top stories: The U.S. Senate will use a procedural maneuver to pass tax legislation through the Senate, GE beat revenue expectations and Sketchers sales are doing extremely well overseas.
Wall Street ends the day with slight losses on uncertainty over the upcoming French election and another sharp drop in crude oil.
Skechers stock was rising by 2.36% to $25.56 on Monday afternoon,
All three major indexes close Friday at record highs for the second consecutive session.
Jim Cramer says the recent stock rally is focused on two main industries.
Companies that marked turnarounds -- for better or worse -- last week.
A positive earnings report from Microsoft and a weaker one from GE pulled markets in different directions for much of the day on Friday.
Honeywell and Microsoft were both rising premarket on earnings beats, while GE and Skechers faltered.
Shares of Skechers were lower Wednesday after Morgan Stanley downgraded its rating on the stock to Equal-Weight from Overweight.
Retailers' results show that differentiation is the key to this new environment.
SKX is likely to go in one direction with the drop in its option prices: lower.
Skechers tanks following its bottom-line second-quarter earnings miss.
The sneaker giant is like Apollo Creed in "Rocky" -- a cocky champ that may be underestimating the competition.
Jim Cramer says Hershey is a play on improving convenience store sales, and as that stock comes in and bottoms, he looks at it as a buy.
Skechers is a long term bet on its fantastic management, says Jim Cramer.
Jim Cramer said he'd be a buyer of gold instead of silver, prefers Nike over other footwear brands and sees Lam Research as a star.
TheStreet's Jim Cramer said that while Skechers (SKX) has a 'sensational' CEO, there is not enough clarity on how the footwear company is doing at any given time.
Higher oil prices are helping stocks like Freeport-McMoran, according to Jim Cramer, portfolio manager of the Action Alerts PLUS charitable.
The ETF gives investors access to consumer stocks while keeping costs and emotions under control.
TheStreet's Jim Cramer says based on valuation, investors should buy Allergan (AGN) over Pfizer (PFE) because the two are moving closer to an acquisition.
TheStreet’s Jim Cramer answered questions from social media on the floor of the New York Stock Exchange.
Many people have no idea what they are doing when they buy or sell.